Morgan Stanley’s Apexigen, Inc. WarrantApexigen, Inc. Warrant APGNW Stock Holding History

Morgan Stanley’s Portfolio APGNW Stock Details APGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-70	Closed	-$2	–	7779
2023 Q2	$2	Buy	+70	New	+$3	﹤0.01%	7639

Other funds holding APGNW

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Morgan Stanley's APGNW Position: Q3 2023 in Review

Morgan Stanley sold out of Apexigen, Inc. WarrantApexigen, Inc. Warrant (APGNW) in Q3 2023, closing a stake of 70 shares — an estimated $2 sold.

Morgan Stanley first reported a position in APGNW in Q2 2023 and held it in 1 quarter. The position peaked at $2 in Q2 2023. 1 fund tracked by Wall St. Rank holds APGNW as of Q3 2023.

Morgan Stanley reported no remaining Apexigen, Inc. WarrantApexigen, Inc. Warrant position as of Q3 2023 after selling out during the quarter.
Morgan Stanley sold 70 Apexigen, Inc. WarrantApexigen, Inc. Warrant shares in Q3 2023, an estimated $2.
Morgan Stanley first reported a position in Apexigen, Inc. WarrantApexigen, Inc. Warrant in Q2 2023 and held it in 1 quarter.
Morgan Stanley's Apexigen, Inc. WarrantApexigen, Inc. Warrant position peaked at $2 in Q2 2023.
1 fund tracked by Wall St. Rank held Apexigen, Inc. WarrantApexigen, Inc. Warrant as of Q3 2023.

Based on Morgan Stanley's 13F filing for Q3 2023, filed 15 Nov 2023.